Clin2
NCT07541781Possibly a fitRecruiting

Sitagliptin for recurrent grade 4 glioma

GliomaGlioblastomaRecurrent GliomaRecurrent GlioblastomaGrade 4 Malignant Glioma of Brain (Disorder)

Treatments studied

Part of Cancer clinical trials.

This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
45 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your grade 4 glioma has come back or progressed after initial treatment.
  • You have not had sitagliptin or bevacizumab for this tumor before.
  • You can swallow whole tablets and are in reasonably good health (ECOG 0-2).
  • Your blood counts, kidney, and liver function are within safe limits.
  • You do not have uncontrolled diabetes, heart problems, or a bleeding disorder.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07003542Recruiting· Phase 2
Sitagliptin for people with high-grade brain tumors

This trial tests whether sitagliptin, a medicine usually used for diabetes, can help people with a fast-growing type of brain tumor (grade 4 glioma). You will take sitagliptin before your planned surgery, and researchers will study how it affects your tumor.

Cleveland, Ohio
NCT06773481Recruiting· Phase 1
BC008-1A injection for recurrent grade 4 glioma

This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.

Beijing, Beijing Municipality
NCT07392957Recruiting· Phase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma

This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.

St Louis, Missouri
NCT05502991Not yet recruiting· Phase 2
Study of two drugs for recurrent glioblastoma

This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.

Zhengzhou, Henan
NCT07670026Recruiting· Phase 2
Stronger treatment after surgery for high-risk glioblastoma

This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.

Hangzhou, Zhejiang
NCT07025226Recruiting· Early Phase 1
Combination drugs and vaccine for glioma with remaining tumor

This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.

Rochester, Minnesota

Hear when a new Glioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.